Supira Medical, Inc. (Supira), a clinical-stage company focused on transforming the percutaneous ventricular assist device (pVAD) market, today announced FDA approval to initiate the SUPPORT II ...
CE Marking and ARCH clinical trial data position the Liverty™ TIPS Stent Graft to expand treatment options for patients with advanced liver disease BD (Becton, Dickinson and Company) (NYSE: BDX), a ...
Brown brings more than 20 years of experience in mitochondrial research and scientific team leadership. Stealth BioTherapeutics (the “Company” or “Stealth”), a commercial-stage biotechnology company ...
Mechanism-Driven Study Design Focused on Capital Efficiency and Accelerated Development for Near-Term Value Creation, Addressing a $2 Billion Potential Target Market Medicus Pharma Ltd. (NASDAQ: MDCX) ...
The new partnership builds on a relationship between Bailey & Galyen in Mansfield TX and the Texas Rangers since 2022, when the firm first became the club's official legal sponsor. Texas consumer law ...
Dealing with both mental health issues and substance use disorders in tandem can feel overwhelming. Many individuals find that symptoms from one disorder often aggravate the other, complicating not ...
Inaugural case performed by spine surgeon Dr. Scott L. Parker highlights the system's strength, versatility, and precision for supporting multi-level spinal constructs Genesys Spine today announced ...
First patient dosed in Opti-GAIN, a first-in-human Phase I/II clinical trial of CTx001 in Geographic Atrophy secondary to AMD Complement Therapeutics GmbH (CTx), a clinical-stage biotechnology company ...
GCC Medical Consumables Market is projected to grow at a steady CAGR of around 4.73% during 2026–2032. According to the latest study published by MarkNtel Advisors, the GCC Medical Consumables Market ...
Dinesh kumar ph D founder and ceo of blend health technologies Hypertension, defined as having a blood pressure at or above 130/80 mm Hg, has often been called the silent killer, putting a person at ...
The RPD Pilot trial builds on the strong results from Verve’s TUSK feasibility trial, which demonstrated an average reduction of approximately 20 mmHg in systolic blood pressure among treated patients ...
The CellTolerance® Test ends years of trial-and-error diets by pinpointing food intolerances through live cellular imaging For millions of Americans suffering from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results